(ILMN) Illumina - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4523271090
Sequencers, Arrays, Consumables, Reagents, Library Prep
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 42.3% |
| Value at Risk 5%th | 65.3% |
| Relative Tail Risk | -6.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -24.86 |
| CAGR/Max DD | -0.17 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.332 |
| Beta | 1.116 |
| Beta Downside | 1.038 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.94% |
| Mean DD | 40.02% |
| Median DD | 42.85% |
Description: ILMN Illumina October 30, 2025
Illumina, Inc. (NASDAQ: ILMN) designs, manufactures, and sells sequencing- and array-based platforms and consumables that enable whole-genome, exome, and targeted-region analysis for research, clinical, and consumer genomics applications across the Americas, Europe, Greater China, APAC, the Middle East, and Africa.
In FY 2023 the company generated roughly $4.5 billion in revenue, growing about 13 % year-over-year, with R&D expenditures representing ~20 % of sales-a reflection of its focus on maintaining a technological edge in next-generation sequencing (NGS). Illumina commands an estimated 70 % share of the global NGS market, driven by declining sequencing costs (now under $600 per human genome) and expanding clinical-diagnostic use cases such as non-invasive prenatal testing and oncology-focused liquid biopsies. The firm’s growth is also tied to broader sector trends, including increasing investment in personalized medicine and the rising demand for high-throughput genomic data in drug discovery.
For a deeper quantitative breakdown of Illumina’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (703.0m TTM) > 0 and > 6% of Revenue (6% = 257.2m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 7.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 19.45% (prev 31.85%; Δ -12.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 1.12b > Net Income 703.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.53b) to EBITDA (1.29b) ratio: 1.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (157.0m) change vs 12m ago -1.88% (target <= -2.0% for YES) |
| Gross Margin 66.20% (prev 63.94%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.33% (prev 73.00%; Δ -2.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.16 (EBITDA TTM 1.29b / Interest Expense TTM 125.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.42
| (A) 0.14 = (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b |
| (B) -0.12 = Retained Earnings (Balance) -726.0m / Total Assets 6.18b |
| (C) 0.17 = EBIT TTM 1.02b / Avg Total Assets 6.10b |
| (D) -0.19 = Book Value of Equity -736.0m / Total Liabilities 3.80b |
| Total Rating: 1.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.72
| 1. Piotroski 8.0pt |
| 2. FCF Yield 4.78% |
| 3. FCF Margin 23.49% |
| 4. Debt/Equity 1.08 |
| 5. Debt/Ebitda 1.18 |
| 6. ROIC - WACC (= 6.93)% |
| 7. RoE 29.98% |
| 8. Rev. Trend -75.73% |
| 9. EPS Trend 30.67% |
What is the price of ILMN shares?
As of December 13, 2025, the stock is trading at USD 134.87 with a total of 1,700,038 shares traded.
Over the past week, the price has changed by +4.58%, over one month by +10.57%, over three months by +41.79% and over the past year by -7.89%.
Over the past week, the price has changed by +4.58%, over one month by +10.57%, over three months by +41.79% and over the past year by -7.89%.
Is ILMN a buy, sell or hold?
Illumina has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ILMN.
- Strong Buy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.8 | -11.1% |
| Analysts Target Price | 119.8 | -11.1% |
| ValueRay Target Price | 137.8 | 2.2% |
ILMN Fundamental Data Overview December 03, 2025
Market Cap USD = 19.78b (19.78b USD * 1.0 USD.USD)
P/E Trailing = 28.861
P/E Forward = 26.3158
P/S = 4.6139
P/B = 8.4358
P/EG = 0.622
Beta = 1.45
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 21.08b USD (19.78b + Debt 2.58b - CCE 1.28b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
FCF Yield = 4.78% (FCF TTM 1.01b / Enterprise Value 21.08b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.41 (Enterprise Value 21.08b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.38% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.12% (E(19.78b)/V(22.36b) * Re(10.13%) + D(2.58b)/V(22.36b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 71.12% ; FCFE base≈822.6m ; Y1≈826.7m ; Y5≈885.7m
Fair Price DCF = 72.68 (DCF Value 11.11b / Shares Outstanding 152.8m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 30.67 | EPS CAGR: 16.74% | SUE: 0.67 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.12 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=14
EPS next Year (2026-12-31): EPS=4.99 | Chg30d=+0.140 | Revisions Net=+14 | Growth EPS=+6.0% | Growth Revenue=+2.1%
P/E Trailing = 28.861
P/E Forward = 26.3158
P/S = 4.6139
P/B = 8.4358
P/EG = 0.622
Beta = 1.45
Revenue TTM = 4.29b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 21.08b USD (19.78b + Debt 2.58b - CCE 1.28b)
Interest Coverage Ratio = 8.16 (Ebit TTM 1.02b / Interest Expense TTM 125.0m)
FCF Yield = 4.78% (FCF TTM 1.01b / Enterprise Value 21.08b)
FCF Margin = 23.49% (FCF TTM 1.01b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.41 (Enterprise Value 21.08b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 695.5m (EBIT 1.02b * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.18 (Net Debt 1.53b / EBITDA 1.29b)
Debt / FCF = 1.52 (Net Debt 1.53b / FCF TTM 1.01b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.38% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 30.55% (EBIT 1.02b / Capital Employed (Equity 2.35b + L.T.Debt 994.0m))
RoIC = 16.04% (NOPAT 695.5m / Invested Capital 4.34b)
WACC = 9.12% (E(19.78b)/V(22.36b) * Re(10.13%) + D(2.58b)/V(22.36b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 71.12% ; FCFE base≈822.6m ; Y1≈826.7m ; Y5≈885.7m
Fair Price DCF = 72.68 (DCF Value 11.11b / Shares Outstanding 152.8m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 30.67 | EPS CAGR: 16.74% | SUE: 0.67 | # QB: 0
Revenue Correlation: -75.73 | Revenue CAGR: -2.68% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.12 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=14
EPS next Year (2026-12-31): EPS=4.99 | Chg30d=+0.140 | Revisions Net=+14 | Growth EPS=+6.0% | Growth Revenue=+2.1%
Additional Sources for ILMN Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle